Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02358473 · ClinicalTrials.gov registry record · Phase 1

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Kyowa Kirin.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
5
Study locations

NCT02358473: Completed Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Kyowa Kirin.

NCT02358473 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Kyowa Kirin. The registered enrollment target is 13 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02358473, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Kyowa Kirin.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.

Conditions Studied

Interventions

  • DRUG Docetaxel
  • BIOLOGICAL mogamulizumab

Study Locations (5)

Texas

  • MD Anderson - Houston
  • Cancer Therapy and Research Center - San Antonio

Indiana

  • Horizon Oncology - Lafayette

Maryland

  • John Hopkins University School of Medicine - Baltimore

Ohio

  • Gabrail Cancer Center Research - Canton

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2015-01
Est. Completion 2016-12
Phase Phase 1
Kyowa Kirin

34 total trials

What the finished NCT02358473 record still lists

NCT02358473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT02358473 lists 5 locations in 4 states (Texas, Indiana, Maryland).

Frequently Asked Questions

What is clinical trial NCT02358473 about?

NCT02358473 is a clinical study titled "Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer". The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.

What is the current status of trial NCT02358473?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-01. Estimated completion is 2016-12.

What conditions does trial NCT02358473 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT02358473?

The interventions under investigation include: Docetaxel (DRUG), mogamulizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02358473?

This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02358473 being conducted?

This trial has 5 study locations across Indiana, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02358473's enrollment target sits among peer trials

13 434th of 454 higher than 19 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02358473, the US trial registry maintained by the National Library of Medicine. NCT02358473 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.